Enhabit Reports Fourth Quarter Results and Issues Full-Year 2025 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq drops as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Leerink Partners on Enhabit Home Health & Hospice (EHAB): 'Very Modest EBITDA Beat with 2025 Guidance Mostly In-Line'
March 6, 2025 1:21 PM ESTLeerink Partners analyst Whit Mayo reiterated a Market Perform rating on Enhabit Home Health & Hospice (NYSE: EHAB).
The analyst comments "Reiterate Market Perform rating. 4Q results look fine with in-line revs, a modest EBITDA beat (+2%), and 2025 guided largely in-line. Home Health again... More
Jefferies Defends Enhabit Home Health & Hospice (EHAB): 'Sell-Off Unwarranted Given Stabilizing KPIs, Defensiveness vs DC, Valuation'
March 6, 2025 1:18 PM ESTJefferies analyst Brian Tanquilut reiterated a Buy rating and $9.50 price target on Enhabit Home Health & Hospice (NYSE: EHAB)
The analyst comments "We maintain our Buy on EHAB and point to Q4 results being "good enough" (slight EBITDA beat) and FY25 guidance bracketing consensus... More
